PD-MitoQUANT

PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
PD-MitoQUANT logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
821522

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
4 497 935
EFPIA in kind
2 293 600
Associated Partners
168 000
Total Cost
6 959 535

Summary

Mitochondria are the powerhouses of our cells. Mutations in the mitochondria appear to be associated with Parkinson’s disease, a neurodegenerative disease that affects around a million people in Europe. It is triggered by the death of neurons that produce a chemical called dopamine; in order to properly work, these neurons need a lot of energy.

Focusing on mitochondria dysfunction in Parkinson’s disease, the PD-MitoQUANT project aims to identify and validate molecular drivers and mechanisms of the condition and discover innovative therapeutic targets that can be further developed by the pharmaceutical companies. Current therapies can cause adverse side effects, and cannot stop, slow or reverse disease progression. This makes the improvement of Parkinson’s disease-related treatments even more urgently needed.

Participants Show participants on map

EFPIA companies
  • H. Lundbeck As, Valby, Denmark
  • Teva Pharmaceutical Industries Limited, Netanya, Israel
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Consiglio Nazionale Delle Ricerche, Roma, Italy
  • Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev, Bonn, Germany
  • Institut Du Cerveau Et De La Moelle Epiniere, Paris, France
  • Royal College Of Surgeons In Ireland, Dublin, Ireland
  • Stichting Katholieke Universiteit, Nijmegen, Netherlands
  • University College London, London, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Genexplain GMBH, Wolfenbuttel, Germany
  • Mimetas BV, Leiden, Netherlands
  • Pintail LTD, Blackrock, Ireland
Associated partners
  • Parkinson'S Disease Society Of Theunited Kingdom Lbg, London, United Kingdom

CONTACT

Project coordinator
Jochen PREHN
ROYAL COLLEGE OF SURGEONS IN IRELAND
JPrehn[at]rcsi.ie